<?xml version="1.0" encoding="UTF-8"?>
<p id="P73">Adefovir is converted intracellularly by cellular kinases to its active metabolite, adefovir diphosphate, which competitively inhibits HBV DNA polymerase.
 <sup>
  <xref ref-type="bibr" rid="R165">165</xref>
 </sup> Although adefovir has the distinction of being the least potent among currently available anti-HBV drugs, it has been used in adults with decompensated liver disease, or with compensated liver disease with evidence of active viral replication, persistently elevated ALT levels, and histologic evidence of active inflammation and fibrosis.
 <sup>
  <xref ref-type="bibr" rid="R164">164</xref>
 </sup>
</p>
